

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $8.06
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 12, 26 |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 6, 26 | Kim Hyong | officer: Chief Medical Officer | S-Sale | 32,479 @ $8.30 | $269.6K |
| UBS |
| maintain |
| Neutral |
| Neutral |
| Oct 12, 26 | TD Cowen | maintain | Buy | Buy |
| Oct 9, 26 | William Blair | downgrade | Outperform | Market Perform |
| Oct 9, 26 | Keybanc | maintain | Overweight | Overweight |
| Oct 9, 26 | JP Morgan | maintain | Overweight | Overweight |
| Oct 6, 26 | Barclays | maintain | Equal Weight | Equal Weight |
| Aug 4, 26 | JP Morgan | maintain | Overweight | Overweight |
| Aug 3, 26 | Raymond James | downgrade | Strong Buy | Outperform |
| May 26, 26 | Barclays | maintain | Equal Weight | Equal Weight |
| Sep 17, 26 |
| Konowiecki Joseph S |
| director, officer: EVP, Corporate Affairs |
| S-Sale |
| 23,511 @ $8.61 |
| $202.4K |
| Sep 14, 26 | Kao John E | director, officer: Chief Executive Officer | S-Sale | 27,400 @ $13.00 | $356.2K |
| Sep 11, 26 | Maroney Dawn Christine | officer: President | S-Sale | 122,707 @ $12.68 | $1.56M |
| Sep 11, 26 | Kao John E | director, officer: Chief Executive Officer | S-Sale | 385,270 @ $12.68 | $4.89M |
| Sep 10, 26 | Kao John E | director, officer: Chief Executive Officer | S-Sale | 172,600 @ $12.96 | $2.24M |
| Aug 14, 26 | Maroney Dawn Christine | officer: President | S-Sale | 5,000 @ $14.00 | $70.00K |
| Aug 10, 26 | Kao John E | director, officer: Chief Executive Officer | S-Sale | 298,000 @ $13.88 | $4.14M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 8, 2026 | 2026-10-08 17:13:20 | View |
| 4 | Oct 7, 2026 | 2026-10-07 16:00:11 | View |
| SC 13G/A | Oct 5, 2026 | 2026-10-05 11:58:09 | View |
| 4 | Sep 18, 2026 | 2026-09-18 16:29:32 | View |
| 4 | Sep 16, 2026 | 2026-09-16 17:57:48 | View |
| 4 | Sep 11, 2026 | 2026-09-11 20:41:04 | View |
| 4 | Sep 11, 2026 | 2026-09-11 20:38:11 | View |
| 4 | Aug 18, 2026 | 2026-08-18 16:01:38 | View |
| SC 13G | Aug 13, 2026 | 2026-08-13 14:02:57 | View |
| 4 | Aug 10, 2026 | 2026-08-10 18:14:18 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | ALHC | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 40.4x | -1078.4x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 57.3x | EPS est. 0.14 | Elevated |
| Price / Book | 6.3x | 14.1x | Discount |
| Price / Sales | 0.4x | 1.2x | Discount |
| EV / EBITDA | 15.1x | 2.0x | Elevated |
| Return on equity | 20.0% | — | Top tier |
| Gross margin | 12.5% | 11.6% | In line |
| Debt / Equity | 1.25 | 1.49 | Moderate |
| Piotroski / Altman Z | 6/9 | Z 4.11 | Safe zone |
Discounted cash flow model
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 37.70 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 82.73 | Oscillator | Sell |
| Williams %R (14) | -26.26 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.56 (Hist 0.21) | Oscillator | Buy |
| Average Directional Index (14) | 37.43 (+DI 15.7 / -DI 34.4) | Trend | Strong Sell |
Stock news · updated daily
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Alignment Healthcare, Inc. (NASDAQ:ALHC) for potential securities fraud after its significant stock drop. If you invested in Alignment securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/alignment-class-action-lawsuit.
Alignment Healthcare (ALHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
| EMA 20 | 8.56 | MA | Strong Sell |
| SMA 20 | 8.21 | MA | Sell |
| EMA 50 | 10.48 | MA | Strong Sell |
| SMA 50 | 10.41 | MA | Strong Sell |
| SMA 200 | 17.14 | MA | Strong Sell |
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | 0.13 | 0.17 | Beat 31.8% | $1.34B |
| Apr 30, 2026 | 0.01 | 0.05 | Beat 400.0% | $1.24B |
| Feb 26, 2026 | -0.15 | -0.05 | Beat 66.7% | $1.01B |
| Oct 30, 2025 | -0.01 | 0.02 | Beat 300.0% | $993.7M |
| Jul 30, 2025 | -0.07 | 0.07 | Beat 200.0% | $1.02B |
| May 1, 2025 | -0.12 | -0.05 | Beat 58.3% | $926.9M |
FY2023 · 10-K disclosure